MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

about

MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q48282223

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@en

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@nl

type

Item

label

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@en

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@nl

prefLabel

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@en

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@nl

P1476

MZH29 is a novel potent inhibi ...... ons in acute myeloid leukemia.

@en

P2093

P Gong

http://www.w3.org/2001/XMLSchema#string

X Wang

http://www.w3.org/2001/XMLSchema#string

Y Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

SYK is a critical regulator of FLT3 in acute myeloid leukemia

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

UCSF Chimera--a visualization system for exploratory research and analysis

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

P2888

leu.2016.297

P304

913-921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2016.297

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Benhong Xu

Wei Ge

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27773927

http://www.w3.org/2001/XMLSchema#string